1Chitkara College of Pharmacy, Chitkara University, Punjab, India
2Chandigarh College of Pharmacy, CGC, Landran, Mohali, India
3University School of Pharmaceutical Sciences, Rayat-Bahra University, Punjab, India
4Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
#Author for Correspondence
Ms. Amandeep Kaur
Assistant Professor, Chandigarh College of Pharmacy, CGC, Landran, Mohali, India, 140307
& PhD Scholar, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401
Email: amandeepsaini2711@gmail.com, amandeep.5464@cgc.edu.in
Pyridine is a well-researched heterocyclic moiety that plays a significant role in a number of biological and medicinal processes. In modern research, pyridine derivative for Protein tyrosine kinases (PTKs) are the most explored of the numerous targets that have been found, confirmed, and inhibited at various cancer hallmarks. In the present study, using in silico approaches 14 pyridine derivatives were evaluated for ADME properties and Insulin receptor (IR) inhibition as potent anti-breast cancer agents. Results of ADME and Docking studies demonstrated that substituted pyridine derivatives bind effectively at the ATP-binding site of insulin receptor, particularly PC12, PC6, and PC7, may function as competitive inhibitors of the kinase domain, thereby blocking signal transduction pathways critical for cancer cell proliferation. Based on in silico studies, the derivatives likely function as competitive inhibitors of insulin receptor kinase as compared to existing market drugs. This inhibition blocks downstream PI3K/Akt and MAPK signaling pathways, thereby reducing tumor proliferation, inducing apoptosis, preventing angiogenesis. These results lead to further research based on synthesis and in-vitro studies.
Keywords: Cancer, PTKs, Drug likeness, ADME and Docking studies.
How to cite this article: Kaur A, Garg M, Goyal A, Rana S, Saloria S, Singh G. Insilco Drug Designing of Novel Pyridine Derivatives to Evaluate Significant Anti-Cancer Activity. Int J Drug Deliv Technol. 2026;16(6s): 796-808; DOI: 10.25258/ijddt.16.6s.107
Source of support: None
Conflict of interest: None